As research on lactate and lactylation in cancer continues to flourish, strategies targeting lactate/lactylation have attracted significant interest as potential anticancer treatments.71–75 Consequently, AZD3965, an MCT1 (monocarboxylate transporter 1) inhibitor, has emerged as the first lactate metabolism-targeting drug currently undergoing a phase I/II clinical trial (NCT01791595) for the treatment of advanced solid tumors and non-Hodgkin lymphoma.76–80. Here, SLC16A1 is linked to non-Hodgkin lymphoma.